收费全文 | 1677篇 |
免费 | 123篇 |
国内免费 | 6篇 |
耳鼻咽喉 | 11篇 |
儿科学 | 44篇 |
妇产科学 | 53篇 |
基础医学 | 278篇 |
口腔科学 | 49篇 |
临床医学 | 183篇 |
内科学 | 330篇 |
皮肤病学 | 17篇 |
神经病学 | 108篇 |
特种医学 | 56篇 |
外科学 | 201篇 |
综合类 | 44篇 |
预防医学 | 134篇 |
眼科学 | 30篇 |
药学 | 127篇 |
中国医学 | 23篇 |
肿瘤学 | 118篇 |
2024年 | 3篇 |
2023年 | 34篇 |
2022年 | 85篇 |
2021年 | 107篇 |
2020年 | 78篇 |
2019年 | 83篇 |
2018年 | 95篇 |
2017年 | 73篇 |
2016年 | 80篇 |
2015年 | 88篇 |
2014年 | 97篇 |
2013年 | 117篇 |
2012年 | 139篇 |
2011年 | 131篇 |
2010年 | 67篇 |
2009年 | 56篇 |
2008年 | 80篇 |
2007年 | 66篇 |
2006年 | 58篇 |
2005年 | 39篇 |
2004年 | 28篇 |
2003年 | 21篇 |
2002年 | 18篇 |
2001年 | 14篇 |
2000年 | 9篇 |
1999年 | 16篇 |
1998年 | 5篇 |
1997年 | 6篇 |
1996年 | 8篇 |
1993年 | 2篇 |
1992年 | 5篇 |
1991年 | 15篇 |
1990年 | 12篇 |
1989年 | 7篇 |
1988年 | 6篇 |
1987年 | 4篇 |
1986年 | 7篇 |
1984年 | 3篇 |
1983年 | 4篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1980年 | 4篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1973年 | 2篇 |
1972年 | 2篇 |
1971年 | 4篇 |
1970年 | 2篇 |
1969年 | 3篇 |
1967年 | 7篇 |
Hypercoagulable state is one of the common findings in beta-thalassemia intermedia (β-TI), particularly in splenectomized patients, with infrequent blood transfusion. Abnormality of the red blood cells (RBC) membrane due to oxidative damage is suggestive of possible etiologies. Membrane lipid peroxidation increases the exposure of phosphatidylserine (PS) that plays a role in the activation of coagulation factors V and X, subsequently initiating thrombosis. Our aim of this study was to find the probable correlation of the alteration of the PS on the RBC outer membrane with the hypercoagulable state in the β-TI patients.
Materials and methods
Our cross-sectional study was conducted on 39 splenectomized β-TI patients and 38 age-matched healthy controls. The mean age was 37 years. Analysis of the PS exposure on the RBCs was performed by fluorescein isothiocyanate (FITC) conjugated AV protein .Measurement of the coagulation factors X, V and antithrombin III (AT-III) was performed. We also checked the D-dimer levels .Analysis was performed by SPSS16.
Results
Fluorescence of FITC-Annexin V labeling on patients RBCs were higher than healthy controls; (2.8 ± 2.2%) of the patients versus (0.4 ± 0.18%) in the control group and was statistically significant (P < 0.05). Mean levels of factor X and AT-III of the patients as compared with the control group decreased and showed significant difference (P < 0.05).
Conclusions
Circulation of thalassemic RBCs, which abnormally possess PS on RBC membrane outer surface, suggests the possibility of the gradual consumption of the coagulation factors in the presence of a chronic coagulability state. 相似文献
The current standard option for iron chelation therapy (ICT) in transfusion-dependent patients with beta-thalassemia is deferoxamine (DFO). We aimed to compare the compliance with DFO vs. deferasirox (Exjade®), a novel oral iron chelator, in patients with transfusion-dependent beta-thalassemia.
Methods
In this cross-sectional study, 220 patients from Southern Iran who were receiving DFO or Exjade® for the last 2 years were investigated in 2012. Satisfaction, compliance, convenience, and life disturbances of the patients with ICT were evaluated. Assessments were performed at four different occasions during 1 year.
Results
According to the results, 114 patients received treatment with DFO and 106 patients were treated with Exjade®. In comparison with the patients who were treated with DFO, those receiving Exjade® reported a significantly higher rate of compliance and convenience (P < 0.05). However, no significant difference was observed between the two groups regarding their satisfaction (P > 0.05). In the DFO group, 44.9% of the patients reported irritation and pain at the injection site.
Conclusions
Considering higher rate of compliance and convenience with Exjade® and the comparable efficacy of these two modalities of ICT documented in previous studies, Exjade® can be used as a preferable choice of ICT in iron-overload patients with beta-thalassemia. 相似文献